Works matching AU Toru Kumagai

Results: 60
    1
    2

    Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

    Published in:
    2020
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Makio, Takeshi;
    • Hara, Satoshi
    Publication type:
    journal article
    3
    4
    5
    6
    7

    Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection.

    Published in:
    Molecular & Clinical Oncology, 2017, v. 7, n. 3, p. 327, doi. 10.3892/mco.2017.1340
    By:
    • YUKI AKAZAWA;
    • MASAHIKO HIGASHIYAMA;
    • KAZUMI NISHINO;
    • JYUNJI UCHIDA;
    • TORU KUMAGAI;
    • TAKAKO INOUE;
    • AYAKO FUJIWARA;
    • TOSHITERU TOKUNAGA;
    • JIRO OKAMI;
    • FUMIO IMAMURA;
    • KEN KODAMA;
    • HISAYUKI KOBAYASHI
    Publication type:
    Article
    8
    9

    Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.

    Published in:
    Japanese Journal of Clinical Oncology, 2021, v. 51, n. 8, p. 1261, doi. 10.1093/jjco/hyab072
    By:
    • Sakai, Hiroshi;
    • Morise, Masahiro;
    • Kato, Terufumi;
    • Matsumoto, Shingo;
    • Sakamoto, Tomohiro;
    • Kumagai, Toru;
    • Tokito, Takaaki;
    • Atagi, Shinji;
    • Kozuki, Toshiyuki;
    • Tanaka, Hiroshi;
    • Chikamori, Kenichi;
    • Shinagawa, Naofumi;
    • Takeoka, Hiroaki;
    • Bruns, Rolf;
    • Straub, Josef;
    • Schumacher, Karl Maria;
    • Paik, Paul K
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1828, doi. 10.1007/s10147-022-02232-7
    By:
    • Sugawara, Shunichi;
    • Kondo, Masashi;
    • Yokoyama, Toshihide;
    • Kumagai, Toru;
    • Nishio, Makoto;
    • Goto, Koichi;
    • Nakagawa, Kazuhiko;
    • Seto, Takashi;
    • Yamamoto, Nobuyuki;
    • Kudou, Kentarou;
    • Asato, Takayuki;
    • Zhang, Pingkuan;
    • Ohe, Yuichiro
    Publication type:
    Article
    24
    25
    26
    27

    Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 13, p. 4501, doi. 10.1002/cam4.3089
    By:
    • Kunimasa, Kei;
    • Hirotsu, Yosuke;
    • Amemiya, Kenji;
    • Nagakubo, Yuki;
    • Goto, Taichiro;
    • Miyashita, Yoshihiro;
    • Kakizaki, Yumiko;
    • Tsutsui, Toshiharu;
    • Otake, Sotaro;
    • Kobayashi, Hiroaki;
    • Higuchi, Rumi;
    • Inomata, Kie;
    • Kumagai, Takashi;
    • Mochizuki, Hitoshi;
    • Nakamura, Harumi;
    • Nakatsuka, Shin‐ichi;
    • Nishino, Kazumi;
    • Imamura, Fumio;
    • Kumagai, Toru;
    • Oyama, Toshio
    Publication type:
    Article
    28

    Hepatoma-Derived Growth Factor Is Involved in Lung Remodeling by Stimulating Epithelial Growth.

    Published in:
    American Journal of Respiratory Cell & Molecular Biology, 2004, v. 30, n. 4, p. 459, doi. 10.1165/rcmb.2003-0013OC
    By:
    • Masahide Mori;
    • Hiroshi Morishita;
    • Hideji Nakamura;
    • Hiroto Matsuoka;
    • Kenya Yoshida;
    • Yoshihiko Kishima;
    • Zhiwei Zhou;
    • Hiroshi Kida;
    • Toshiki Funakoshi;
    • Sho Goya;
    • Mitsuhiro Yoshida;
    • Toru Kumagai;
    • Isao Tachibana;
    • Yoichi Yamamoto;
    • Ichiro Kawase;
    • Seiji Hayashi
    Publication type:
    Article
    29

    Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis.

    Published in:
    DNA & Cell Biology, 2007, v. 26, n. 3, p. 178, doi. 10.1089/dna.2006.0573
    By:
    • Furukawa, Mitsugi;
    • Nagatomo, Izumi;
    • Kumagai, Toru;
    • Yamadori, Tadahiro;
    • Takahashi, Ryo;
    • Yoshimura, Mana;
    • Yoneda, Tsutomu;
    • Takeda, Yoshito;
    • Goya, Sho;
    • Matsuoka, Hiroto;
    • Kijima, Takashi;
    • Yoshida, Mitsuhiro;
    • Osaki, Tadashi;
    • Tachibana, Isao;
    • Greene, Mark I.;
    • Kawase, Ichiro
    Publication type:
    Article
    30

    The Extracellular Domain of p185<sup>c-neu</sup> Induces Density-Dependent Inhibition of Cell Growth in Malignant Mesothelioma Cells and Reduces Growth of Mesothelioma In Vivo.

    Published in:
    DNA & Cell Biology, 2006, v. 25, n. 9, p. 530, doi. 10.1089/dna.2006.25.530
    By:
    • Yoneda, Tsutomu;
    • Kumagai, Toru;
    • Nagatomo, Izumi;
    • Furukawa, Mitsugi;
    • Yamane, Hiroyuki;
    • Hoshino, Shigenori;
    • Mori, Masahide;
    • Takeda, Yoshito;
    • Horai, Takeshi;
    • Nishida, Sumiyuki;
    • Watanabe, Dai;
    • Kijima, Takashi;
    • Yoshida, Mitsuhiro;
    • Osaki, Tadashi;
    • Tachibana, Isao;
    • Greene, Mark I.;
    • Kawase, Ichiro
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37

    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

    Published in:
    2021
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Matsumoto, Hirotaka;
    • Hirano, Katsuya;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Tanaka, Satoshi;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Mori, Masahide;
    • Nagata, Kenji
    Publication type:
    journal article
    38

    Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes.

    Published in:
    Journal of Cell Biology, 2003, v. 161, n. 5, p. 945, doi. 10.1083/jcb.200212031
    By:
    • Takeda, Yoshito;
    • Tachibana, Isao;
    • Miyado, Kenji;
    • Kobayashi, Masatoshi;
    • Miyazaki, Toru;
    • Funakoshi, Toshiki;
    • Kimura, Hiromi;
    • Yamane, Hiroyuki;
    • Saito, Yoshiyuki;
    • Goto, Hiroyuki;
    • Yoneda, Tsutomu;
    • Yoshida, Mitsuhiro;
    • Kumagai, Toru;
    • Osaki, Tadashi;
    • Hayashi, Seiji;
    • Kawase, Ichiro;
    • Mekada, Eisuke
    Publication type:
    Article
    39
    40
    41
    42
    43

    Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 2, p. 361, doi. 10.1007/s10637-021-01203-5
    By:
    • Tamiya, Motohiro;
    • Fujikawa, Kei;
    • Suzuki, Hidekazu;
    • Yokoyama, Toshihide;
    • Uenami, Takeshi;
    • Tamiya, Akihiro;
    • Sato, Yuki;
    • Saito, Go;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Hirashima, Tomonori;
    • Fukuda, Yasushi;
    • Kanazu, Masaki;
    • Hosoya, Kazutaka;
    • Suzuki, Takuji;
    • Ueno, Kiyonobu;
    • Fujimoto, Daichi;
    • Kumagai, Toru;
    • Teramukai, Satoshi
    Publication type:
    Article
    44

    Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 4, p. 1106, doi. 10.1007/s10637-021-01076-8
    By:
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Suzuki, Hidekazu;
    • Taniguchi, Yoshihiko;
    • Katayama, Kanako;
    • Minomo, Shojiro;
    • Nakao, Keiko;
    • Takeuchi, Naoko;
    • Matsuda, Yoshinobu;
    • Naito, Yujiro;
    • Shiroyama, Takayuki;
    • Okamoto, Norio;
    • Okishio, Kyoichi;
    • Kumagai, Toru;
    • Atagi, Shinji;
    • Imamura, Fumio;
    • Hirashima, Tomonori
    Publication type:
    Article
    45
    46

    Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 1, p. 211, doi. 10.1007/s10637-019-00882-5
    By:
    • Kawachi, Hayato;
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Ishii, Seigo;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Fukuda, Yasushi;
    • Yokoyama, Toshihide;
    • Kominami, Ryota;
    • Fujimoto, Daichi;
    • Hosoya, Kazutaka;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Makio, Takeshi;
    • Hara, Satoshi;
    • Kumagai, Toru
    Publication type:
    Article
    47

    Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

    Published in:
    Investigational New Drugs, 2019, v. 37, n. 6, p. 1266, doi. 10.1007/s10637-019-00843-y
    By:
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Hosoya, Kazutaka;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Fukuda, Yasushi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Kinoshita, Yoshinori;
    • Hara, Satoshi;
    • Kumagai, Toru;
    • Fujimoto, Daichi
    Publication type:
    Article
    48
    49
    50